Despite it being preventable and curable, tuberculosis (TB) is still a leading cause of morbidity and mortality globally. The COVID-19 pandemic further exacerbated TB’s adverse impact as case notifications plummeted and mortality increased for the first time in over a decade.
JSI programs focus on enhancing high-quality prevention and treatment interventions through partnering with national TB programs and other local public and private partners, to ensure continued person-centered care, treatment, and prevention. We focus on all steps of the TB cascade including TB preventive treatment (TPT), infection prevention and control, case finding, diagnosis, and treatment for drug-sensitive (DS) and multidrug-resistant (MDR) TB. We support comprehensive systems to increase demand for and use of TB data and provide technical assistance, global guidance, and tools to support data utilization.
We strive to build lasting relationships to produce better health outcomes for all.
